Management of Medication-Related Osteonecrosis of the Jaw

Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ. Successful treatment may be that which results in a cure, with complete mucosal coverage and elimination of disease, or that which improves the quality of life without a cure (palliation). Helping patients to understand the chronicity and potential progression of the disease is essential to a satisfactory outcome. This review aims to share our treatment approach to patients with MRONJ. Treatment can be divided into medical and surgical therapies.